Search by Drug Name, NDC or Jcode

    Internal Navigation

    HCPCS Details

    HCPC Q2054
    Short Description Lisocabtagene mara car pos t
    Long Description Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
    Pricing indicator 51
    Coverage code C
    ASC payment group code
    BETOS2 code O1E
    Action code N
    Type of service 1
    Effective date 2021-10-01
    Date Added 2021-10-01

    HCPCS/NDC Cross-Walk

    NDC HCPC Description Drug Name Labeler Name HCPCS Dosage PKG Size PKG QTY Bill Units Bill Units PKG
    73153090001 Q2054 Lisocabtagene mara car pos t Breyanzi JUNO THERAPEUTICS, INC. WHOLLY OWNED SUBSIDIARIES OF BRISTOL MYERS SQUIBB Up to 110 million CAR-positive viable T cells, per therapeutic dose 1 1 1 1
    The ASP crosswalks are maintained by the Division of Data Analysis and Market Based Pricing to support ASP-based Medicare Part B payments only. The crosswalks are intended to help the public (including entities that submit manufacturer ASP data and providers who bill for drugs) understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes. The crosswalks are not intended to be a comprehensive list of all drugs/NDCs available in the United States. The NDC to HCPCS Crosswalk also includes information on the NDC package size and the number of billable units (as defined by the HCPCS code descriptor). Comments on the file may be sent to [email protected].

    HCPCS Billing Calculator

    Dosage given to patient (per dose)
    HCPCS Dosage Up to 110 million CAR-positive viable T cells, per therapeutic dose
    HCPCS/CPT Billing Units 0.0090909090909091
    Total doses ordered
    Billing Units 0.0090909090909091